Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Two treatment approaches using donor or engineered NK cells led to remission in people with lymphoma and leukemia.
Two-year follow-up showed that Lumakras prolonged treatment response and had a favorable safety profile.
Individuals considered at high risk were 25 times more likely to develop pancreatic cancer within three years.
People with a specific variant of the CTLA-4 gene had exceptionally good responses to PD-1 checkpoint inhibitors.
Patients with recurrent lesions genetically distinct from the primary tumor may require different treatment.
Researchers identified 128 PSA-associated genetic variants, including 82 new ones, which they used to build a risk score.
A vaccine designed to enhance T-cell activity could help CAR-T therapy work better against solid tumors.
Clinical trials that test new cancer drugs or combinations seldom account for other medications a patient may be taking.
Minimal residual disease status may not be as strong a predictor of relapse in Latino children.
CoVac-1 induced T-cell responses in about 90% of immunocompromised people with impaired B-cell function.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.